Urinary basic fetoprotein in the diagnosis and follow-up of patients with urothelial carcinoma

Cancer

Volumn 77, Issue 8, 1996, Pages 1529-1534

  Kigure, Teruaki ^a,b   Wakayama, Yukiko ^a   Satoh, Yoshinobu ^a   Fujieda, Nobuo ^a   Yoshida, Kouki ^a   Harada, Tadashi ^a  

^a AKITA UNIVERSITY   (Japan)

^b Nakadori Hospital   (Japan)

Author keywords

immunohistochemistry; tumor marker; urinary basic fetoprotein; urothelial carcinoma

Indexed keywords

FETOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; ELECTROIMMUNOASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; ISOELECTRIC POINT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UROGENITAL TRACT TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EVALUATION STUDIES; FEMALE; FETAL PROTEINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; URINE; UROLOGIC DISEASES; UROLOGIC NEOPLASMS;

EID: 0029915268     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1529::AID-CNCR16>3.0.CO;2-1     Document Type: Article

References (18)

1. Greene LF, Hanash KA, Farrow GM. Benign papilloma or papillary carcinoma of the bladder? J Urol 1973;110:205-7.
2. Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-80.
3. Soloway MS. Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 1980;123:461-6.
4. Papanicolaou GN. Cytologic studies in diagnosis of carcinoma. J Int Coll Surg 1954;21:419-26.
5. Hall RR, Laurence DJR, Neville AM, Wallace DM. Carcinoembryonic antigen and urothelial carcinoma. Br J Urol 1973;45:88-92.
6. Fleisher M, Grabstald H, Whitmore WF Jr, Pinsky CM, Oettgen HF, Schwartz MK. The clinical utility of plasma and urinary carcinoembryonic antigen in patients with genitourinary disease. J Urol 1977;117:635-7.
7. Hetherington JW, Ewing R, Cooper EH. Evaluation of a double-monoclonal radioimmunoassay for the measurement of carcinoembryonic antigen in the urine of patients with bladder cancer. Eur Urol 1986;12:270-3.
8. Kumar S, Costello CB, Grashan RW, Bjorklund B. The clinical significance of tissue polypeptide antigen (TPA) in the urine of bladder cancer patients. Br J Urol 1981;53:578-81.
9. Guirguis R, Schiffmann E, Liu B, Birkbeck D, Engel J, Liotta L. Detection of autocrine motility factor in urine as a marker of bladder cancer. J Natl Cancer Inst 1988;80:1203-11.
10. Malpani K, Metcalfe SM, Hinchliffe A. B5 tumor marker and urine cytology in diagnosis and follow-up of transitional cell bladder cancer. Br J Urol 1989;64:257-62.
11. Ishii M. A new carcinoembryonic protein characterized by basic property. Scand J Immunol 1978;8(Suppl):611-20.
12. Harada K, Morishita S, Itani A, Nagata H, Hamami G, Ishii M, et al. Clinical evaluation of basic fetoprotein in testicular cancer. J Urol 1987;138:1178-80.
13. Gohji K, Ishii M, Nagata H, Matsumoto O, Kamidono S. Serum basic fetoprotein in patients with renal cell carcinoma. Cancer 1990;65:1405-11.
14. Hermanek P, Sobin LH. UICC TNM Classification of malignant tumors. 4th edition. Berlin: Springer-Verlag, 1992.
15. Engvall E, Perlmann P. Enzyme linked immunoassay (ELISA) quantitative assay of IgG. Immunochemistry 1971;8:871-4.
16. Ishii M. Basic fetoprotein. Igakunoayumi 1978;106:273-81.
17. Ishii M, Arai K, Takemori Y, Akazawa S, Kanda Y, Komatsu Y, et al. Production of monoclonal anti-basic fetoprotein (BFP) and usefulness of monoclonal anti-BFP for immunodiagnosis of human cancer. Tumor Res 1983;18(special issue):75-86.
18. Tsuji T, Yonese J, Kojima S, Tari K, Ishii M, Seino Y. The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies. Jpn J Urol 1990;81:829-34.